Drugmakers probed in Italy over possible agreement over eye treatment ranibizumab
( June 6, 2024, 07:37 GMT | Official Statement) -- MLex Summary: Several drugmakers — including Samsung Bioepis, Novartis and Biogen — are being probed by the Italian antitrust authority over a possible coordination of commercial strategies to delay the entry of Byooviz onto the domestic market, the watchdog said today. Byooviz is a biosimilar drug based on the active ingredient ranibizumab, used in the treatment of serious eye diseases. Surprise visits were carried out on May 28, by antitrust officials in Italy and the Netherlands.Statement follows. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.